Return Peptide Library
VK2735
BLevel 1 evidenceVK2735
GLP-1 and incretin receptor agonists
Basic Information
Categories
GLP-1/GIP dual receptor agonist
Overview
Viking Therapeutics' dual GLP-1/GIP receptor agonist in late-stage development for obesity.
Efficacy Rating
Study of GLP-1 and GIP
Evidence Level
Grade B
Evidence Type
No data available
Confidence
No data available
China Regulatory Status
Cosmetic Ingredient Directory
No data available
Food/Supplements
No data available
Medicine
No data available
Similar Peptide Recommendations
ASC35
ASC35
DGLP-1 and incretin receptor agonists
Study of GLP-1 and GIP
MBX 4291
MBX 4291
DGLP-1 and incretin receptor agonists
Study of GLP-1 and GIP
Albiglutide
Albiglutide
BGLP-1 and incretin receptor agonists
GLP-1 RA, type 2 diabetes mellitus, discontinued
Semaglutide
Ecenoglutide
BGLP-1 and incretin receptor agonists
GLP-1, weight loss, biased agonist
Disclaimer
The content on this platform is for educational and informational purposes only and does not constitute medical advice, formulation guidance, or a guarantee of regulatory compliance. All efficacy claims are labeled with their evidence level; please consult a professional before making any decisions.